{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:22:28Z","timestamp":1794118948261,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"LSH-TKI","award":["LSHM16025"],"award-info":[{"award-number":["LSHM16025"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13195-019-0487-y","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:02:48Z","timestamp":1555372968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Personalized risk for clinical progression in cognitively normal subjects\u2014the ABIDE project"],"prefix":"10.1186","volume":"11","author":[{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid S.","family":"van Maurik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinde E. R.","family":"Slot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander C. J.","family":"Verfaillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa D.","family":"Zwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke H.","family":"Bouwman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels D.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike P.","family":"Wattjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Molinuevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Rami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Wolfsgruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Berkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,16]]},"reference":[{"key":"487_CR1","unstructured":"Prince M, Anders M, Guerchet M, et al. The global impact of dementia. An analysis of prevalence, incidence, cost and trends. London: Published by Alzheimer\u2019s Disease International (ADI); 2015."},{"key":"487_CR2","volume-title":"Dementia: a public health priority","author":"Organization WH","year":"2012","unstructured":"Organization WH. Dementia: a public health priority. Geneva: World Health Organization; 2012."},{"issue":"10043","key":"487_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, et al. Alzheimer\u2019s disease. Lancet. 2016;388(10043):505\u201317.","journal-title":"Lancet."},{"issue":"12","key":"487_CR4","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1001\/jamaneurol.2017.2712","volume":"74","author":"IS Maurik van","year":"2017","unstructured":"van Maurik IS, Zwan MD, Tijms B, et al. Interpreting biomarker results in individual MCI patients - the ABIDE project. JAMA Neurology. 2017;74(12):1481\u201391.","journal-title":"JAMA Neurology"},{"issue":"12","key":"487_CR5","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(12)70228-4","volume":"11","author":"EM Reiman","year":"2012","unstructured":"Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11(12):1048\u201356.","journal-title":"Lancet Neurol"},{"issue":"3","key":"487_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/01.wad.0000184005.22611.cc","volume":"19","author":"JC Morris","year":"2005","unstructured":"Morris JC. Early-stage and preclinical Alzheimer disease. Alzheimer Dis Assoc Disord. 2005;19(3):163\u20135.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"487_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392.","journal-title":"Alzheimers Dement"},{"key":"487_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"C Jack","year":"2018","unstructured":"Jack C, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"13","key":"487_CR9","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1212\/WNL.0b013e31826c1a8d","volume":"79","author":"L Scheef","year":"2012","unstructured":"Scheef L, Spottke A, Daerr M, et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology. 2012;79(13):1332\u20139.","journal-title":"Neurology."},{"key":"487_CR10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.dadm.2016.10.007","volume":"5","author":"SC Verfaillie","year":"2016","unstructured":"Verfaillie SC, Tijms B, Versteeg A, et al. Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. Alzheimers Dement (Amst). 2016;5:43\u201352.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"12","key":"487_CR11","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.neurobiolaging.2005.10.010","volume":"27","author":"F Jessen","year":"2006","unstructured":"Jessen F, Feyen L, Freymann K, et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging. 2006;27(12):1751\u20136.","journal-title":"Neurobiol Aging"},{"issue":"1\u20132","key":"487_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000439258","volume":"16","author":"A Sierra-Rio","year":"2016","unstructured":"Sierra-Rio A, Balasa M, Olives J, et al. Cerebrospinal fluid biomarkers predict clinical evolution in patients with subjective cognitive decline and mild cognitive impairment. Neurodegener Dis. 2016;16(1\u20132):69\u201376.","journal-title":"Neurodegener Dis"},{"issue":"3","key":"487_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3233\/JAD-150109","volume":"47","author":"E Hessen","year":"2015","unstructured":"Hessen E, Nordlund A, Stalhammar J, et al. T-tau is associated with objective memory decline over two years in persons seeking help for subjective cognitive decline: a report from the Gothenburg-Oslo MCI study. J Alzheimers Dis. 2015;47(3):619\u201328.","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"487_CR14","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/cns.12395","volume":"21","author":"Y Sun","year":"2015","unstructured":"Sun Y, Yang FC, Lin CP, Han Y. Biochemical and neuroimaging studies in subjective cognitive decline: progress and perspectives. CNS Neurosci Ther. 2015;21(10):768\u201375.","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"487_CR15","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3233\/JAD-161252","volume":"58","author":"S Wolfsgruber","year":"2017","unstructured":"Wolfsgruber S, Polcher A, Koppara A, et al. Cerebrospinal fluid biomarkers and clinical progression in patients with subjective cognitive decline and mild cognitive impairment. J Alzheimers Dis. 2017;58(3):939\u201350.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"487_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jalz.2012.08.004","volume":"9","author":"AC Harten van","year":"2013","unstructured":"van Harten AC, Visser PJ, Pijnenburg YA, et al. Cerebrospinal fluid Abeta42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement. 2013;9(5):481\u20137.","journal-title":"Alzheimers Dement"},{"key":"487_CR17","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/ana.24921","volume":"81","author":"BM Tijms","year":"2017","unstructured":"Tijms BM, Bertens D, Slot RE, et al. Low normal CSF Abeta42 levels predict clinical progression in non-demented subjects. Ann Neurol. 2017;81:749\u201353.","journal-title":"Ann Neurol."},{"issue":"1","key":"487_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13195-017-0261-y","volume":"9","author":"JD Grill","year":"2017","unstructured":"Grill JD, Apostolova LG, Bullain S, et al. Communicating mild cognitive impairment diagnoses with and without amyloid imaging. Alzheimers Res Ther. 2017;9(1):35.","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"487_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","volume":"16","author":"GB Frisoni","year":"2017","unstructured":"Frisoni GB, Boccardi M, Barkhof F, et al. Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers. Lancet Neurol. 2017;16(8):661\u201376.","journal-title":"Lancet Neurol"},{"issue":"1","key":"487_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/JAD-132306","volume":"41","author":"WM Flier van der","year":"2014","unstructured":"van der Flier WM, Pijnenburg YA, Prins N, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis. 2014;41(1):313\u201327.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"487_CR21","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM Flier van der","year":"2018","unstructured":"van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: performing research to optimize care. J Alzheimers Dis. 2018;62(3):1091\u2013111.","journal-title":"J Alzheimers Dis"},{"issue":"Suppl 1","key":"487_CR22","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/s00406-014-0539-z","volume":"264","author":"F Jessen","year":"2014","unstructured":"Jessen F. Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer\u2019s disease. Eur Arch Psychiatry Clin Neurosci. 2014;264(Suppl 1):S3\u20137.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"3","key":"487_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303\u20138.","journal-title":"Arch Neurol"},{"issue":"3","key":"487_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"487_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"487_CR26","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ana.22628","volume":"71","author":"CR Jack Jr","year":"2012","unstructured":"Jack CR Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer\u2019s Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71(6):765\u201375.","journal-title":"Ann Neurol"},{"key":"487_CR27","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9:2456\u201377.","journal-title":"Brain."},{"issue":"2","key":"487_CR28","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.43.2.250","volume":"43","author":"GC Roman","year":"1993","unstructured":"Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250\u201360.","journal-title":"Neurology."},{"issue":"3","key":"487_CR29","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.neuroimage.2011.02.046","volume":"56","author":"B Patenaude","year":"2011","unstructured":"Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage. 2011;56(3):907\u201322.","journal-title":"Neuroimage."},{"issue":"4","key":"487_CR30","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.neuroimage.2012.03.074","volume":"61","author":"V Popescu","year":"2012","unstructured":"Popescu V, Battaglini M, Hoogstrate WS, et al. Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1 images in multiple sclerosis. Neuroimage. 2012;61(4):1484\u201394.","journal-title":"Neuroimage."},{"issue":"9","key":"487_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/BF00868807","volume":"242","author":"P Scheltens","year":"1995","unstructured":"Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol. 1995;242(9):557\u201360.","journal-title":"J Neurol"},{"issue":"5","key":"487_CR32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000117270","volume":"36","author":"F Pasquier","year":"1996","unstructured":"Pasquier F, Leys D, Weerts JG, et al. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol. 1996;36(5):268\u201372.","journal-title":"Eur Neurol"},{"issue":"22","key":"487_CR33","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73(22):1914\u201322.","journal-title":"Neurology."},{"issue":"6","key":"487_CR34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1159\/000313534","volume":"29","author":"MI Kester","year":"2010","unstructured":"Kester MI, Boelaarts L, Bouwman FH, et al. Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Dement Geriatr Cogn Disord. 2010;29(6):491\u20137.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"487_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/1536867X1101100104","volume":"11","author":"M Cefalu","year":"2011","unstructured":"Cefalu M. Pointwise confidence intervals for the covariate-adjusted survivor function in the Cox model. Stata J. 2011;11(1):64\u201381.","journal-title":"Stata J"},{"issue":"6","key":"487_CR36","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","volume":"128","author":"JF Crary","year":"2014","unstructured":"Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755\u201366.","journal-title":"Acta Neuropathol"},{"issue":"8","key":"487_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41582-018-0032-9","volume":"14","author":"MT Ferretti","year":"2018","unstructured":"Ferretti MT, Iulita MF, Cavedo E, et al. Sex differences in Alzheimer disease - the gateway to precision medicine. Nat Rev Neurol. 2018;14(8):457\u201369.","journal-title":"Nat Rev Neurol"},{"issue":"16","key":"487_CR38","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1212\/WNL.0b013e3182166e96","volume":"76","author":"BC Dickerson","year":"2011","unstructured":"Dickerson BC, Stoub TR, Shah RC, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology. 2011;76(16):1395\u2013402.","journal-title":"Neurology."},{"issue":"2","key":"487_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u201316.","journal-title":"Lancet Neurol"},{"issue":"7","key":"487_CR40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1474-4422(09)70139-5","volume":"8","author":"PJ Visser","year":"2009","unstructured":"Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer\u2019s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8(7):619\u201327.","journal-title":"Lancet Neurol"},{"issue":"6","key":"487_CR41","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2014;10(6):844\u201352.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"487_CR42","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jalz.2016.09.012","volume":"13","author":"JL Molinuevo","year":"2017","unstructured":"Molinuevo JL, Rabin LA, Amariglio R, et al. Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2017;13(3):296\u2013311.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"487_CR43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jalz.2018.10.003","volume":"15","author":"RER Slot","year":"2019","unstructured":"Slot RER, Sikkes SAM, Berkhof J, et al. Subjective cognitive decline and rates of incident Alzheimer\u2019s disease and non-Alzheimer\u2019s disease dementia. Alzheimers Dement. 2019;15(3):465\u201376. https:\/\/doi.org\/10.1016\/j.jalz.2018.10.003 .","journal-title":"Alzheimers Dement"},{"issue":"9","key":"487_CR44","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","volume":"87","author":"J Wang","year":"2016","unstructured":"Wang J, Logovinsky V, Hendrix SB, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer\u2019s disease trials. J Neurol Neurosurg Psychiatry. 2016;87(9):993\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"487_CR45","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1111\/j.1532-5415.2011.03732.x","volume":"59","author":"SA Sikkes","year":"2011","unstructured":"Sikkes SA, Visser PJ, Knol DL, et al. Do instrumental activities of daily living predict dementia at 1- and 2-year follow-up? Findings from the development of screening guidelines and diagnostic criteria for predementia Alzheimer\u2019s disease study. J Am Geriatr Soc. 2011;59(12):2273\u201381.","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"487_CR46","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10916-018-1071-x","volume":"42","author":"B Bratic","year":"2018","unstructured":"Bratic B, Kurbalija V, Ivanovic M, Oder I, Bosnic Z. Machine learning for predicting cognitive diseases: methods, data sources and risk factors. J Med Syst. 2018;42(12):243.","journal-title":"J Med Syst"},{"key":"487_CR47","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.trci.2017.04.002","volume":"3","author":"M Kunneman","year":"2017","unstructured":"Kunneman M, Pel-Littel R, Bouwman FH, et al. Patients\u2019 and caregivers\u2019 views on conversations and shared decision making in diagnostic testing for Alzheimer\u2019s disease: the ABIDE project. Alzheimers Dement. 2017;3:314\u201322.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"487_CR48","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2217\/fnl.10.31","volume":"5","author":"JS Roberts","year":"2010","unstructured":"Roberts JS, Tersegno SM. Estimating and disclosing the risk of developing Alzheimer\u2019s disease: challenges, controversies and future directions. Future Neurol. 2010;5(4):501\u201317.","journal-title":"Future Neurol"},{"issue":"7618","key":"487_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature."},{"issue":"3","key":"487_CR50","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2217\/nmt.13.25","volume":"3","author":"JS Roberts","year":"2013","unstructured":"Roberts JS, Dunn LB, Rabinovici GD. Amyloid imaging, risk disclosure and Alzheimer\u2019s disease: ethical and practical issues. Neurodegener Dis Manag. 2013;3(3):219\u201329.","journal-title":"Neurodegener Dis Manag"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0487-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-019-0487-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0487-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T12:53:19Z","timestamp":1607259199000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-019-0487-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,16]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["487"],"URL":"https:\/\/doi.org\/10.1186\/s13195-019-0487-y","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,16]]},"assertion":[{"value":"14 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local Medical Ethical Committee. All patients provided written informed consent for their clinical data to be used for research purposes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Prins serves on the advisory board of Boehringer Ingelheim and Probiodrug and on the DSMB of Abbvie\u2019s M15-566 trial. He has provided consultancy services for Sanofi, Takeda, and Kyowa Kirin Pharmaceutical Development. NDP is the CEO and co-owner of the Alzheimer Research Center, Amsterdam, the Netherlands.C. Teunissen serves on the advisory board of Fujirebio and Roche, received research consumables from Euroimmun, IBL, Fujirebio, Invitrogen, and Mesoscale Discovery; performed contract research for IBL, Shire, Boehringer, Roche, and Probiodrug; and received grants from the European Commission, the Dutch Research Council (ZonMW), Association of Frontotemporal Dementia\/Alzheimer\u2019s Drug Discovery Foundation, ISAO, and the Alzheimer\u2019s Drug Discovery Foundation.Dr. Scheltens has acquired grant support (for the institution) from GE Healthcare, Danone Research, Piramal, and MERCK. In the past 2\u2009years, he has received consultancy\/speaker fees (paid to the institution) from Lilly, GE Healthcare, Novartis, Sanofi, Nutricia, Probiodrug, Biogen, Roche, Avraham, and EIP Pharma.Dr. Barkhof serves as a consultant for Biogen-Idec, Janssen Alzheimer Immunotherapy, Bayer-Schering, Merck-Serono, Roche, Novartis, Genzume, and Sanofi-aventis; has received sponsoring from EU-H2020, NIHR-UCLH, NOW, SMSR, TEVA, Novartis, Toshiba; and serves on the editorial boards of Radiology, Brain, Neuroradiology, MSJ, and Neurology.Dr. Peters is on scientific advisory boards for Roche, Kyowa Kirin, Novartis, Lilly, and Piramal. He has received funding for travel or speaker honoraria from GSK, Nutricia, and Merck Serono. He has acted as a consultant for Affiris and Roche. He has received research support from Affiris, Piramal, BMS, Eli Lilly, Pfizer, Servier, TRX Pharmaceuticals, Lundbeck, and Genentech.Dr. Jessen has received consultation board honoraria and speakers fees from AC Immune, Lilly, GE Healthcare, Janssen, USB, Schwabe, Esai, Pfizer, Novartis, and Roche. He has received a research grant paid to his institution from Schwabe.Dr. van der Flier performs contract research for Biogen MA Inc. Research programs of W.M.v.d.F. have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, Cardiovasculair Onderzoek Nederland, Stichting Dioraphte, Gieskes-Strijbis Fonds, Boehringer Ingelheim, Piramal Neuroimaging, Roche BV, Janssen Stellar, and Combinostics. All funding is paid to her institution.van Maurik, Slot, Verfaillie, Dr. Zwan, Dr. Bouwman, Dr. Wattjes, Dr. Wolfsgruber, and Dr. Berkhof declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"33"}}